Toxicity, quality of life, and functional outcomes of 176 hypopharyngeal cancer patients treated by (Chemo)radiation: The impact of treatment modality and radiation technique

Laryngoscope

Volumn 122, Issue 8, 2012, Pages 1789-1795

  Al Mamgani, Abrahim ^a   Mehilal, Robert ^a   Van Rooij, Peter H ^a   Tans, Lisa ^a   Sewnaik, Aniel ^a   Levendag, Peter C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

chemotherapy; Head and neck; hypopharynx; quality of life; radiation therapy

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DYSPHAGIA; EVENT FREE SURVIVAL; FEEDING APPARATUS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; HYPOPHARYNX CANCER; INFECTION; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LARYNGECTOMY; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; MUCOSAL DISEASE; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DERMATITIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN TOXICITY; SURVIVAL TIME; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; COOPERATIVE BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 84864418391     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23387     Document Type: Article

References (10)

1. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
2. Lambert L, Fortin B, Soulieres D, et al. Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding? Int J Radiat Oncol Biol Phys 2010; 76: 398-402.
3. Lefebvre JL, Ang KK,. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 2009; 73: 1293-1303.
4. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36: 1796-1807. (Pubitemid 30639500)
5. Dirix P, Nuyts S,. Value of intensity-modulated radiotherapy in stage IV head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 78: 1373-1380.
6. Langendijk JA, Doornaert P, Rietveld DH, et al. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 2009; 90: 189-195.
7. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
8. Little M, Schipper M, Feng FY, et al. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys In press.
9. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007; 85: 64-73. (Pubitemid 47562584)
10. Schulz U, Mohamed NE,. Turning the tide: benefit finding after cancer surgery. Soc Sci Med 2004; 59: 653-662. (Pubitemid 38622307)